Welcome to Paid Research Studies




  • Conditions:   Acute Myeloid Leukemia;   Relapsed/Refractory Acute Myeloid Leukemia
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Condition:   Hematologic Malignancies
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Lymphoma,Non-Hodgkin;   Lymphoma, Hodgkin;   Lymphoma, Follicular;   Marginal Zone Lymphoma;   Large Cell Lymphoma;   Mantle-Cell Lymphoma;   Gray Zone Lymphoma;   Burkitt Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Cyclophosphamide
    Sponsor:   University of Arizona
    Recruiting

  • Condition:   Metastatic Thyroid Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Sirolimus
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   Leukemia, Not Otherwise Specified;   Leukemia, Other
    Interventions:   Drug: Cyclophosphamide;   Other: Specimen collection
    Sponsor:   Atrium Health
    Recruiting

  • Condition:   Lymphocytic Leukemia
    Interventions:   Drug: NeoVax;   Drug: Cyclophosphamide
    Sponsors:   Dana-Farber Cancer Institute;   Oncovir, Inc.;   Neon Therapeutics, Inc.
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Higher Risk Myelodysplastic Syndrome
    Interventions:   Drug: Nivolumab;   Drug: Stage 1 Arm 1: Low dose Cyclophosphamide (CTX);   Drug: Stage 1 Arm 2: Low dose Cyclophosphamide (CTX);   Drug: Stage 2: Low dose Cyclophosphamide (CTX)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   GVHD;   Hematologic Neoplasms
    Interventions:   Drug: Cyclophosphamide;   Drug: abatacept;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsors:   Dimitrios Tzachanis, MD PhD;   Bristol-Myers Squibb
    Not yet recruiting

  • Condition:   Solid Tumors
    Interventions:   Procedure: Production of Genetically-modified T cells;   Drug: Cyclophosphamide;   Device: IP Catheter Insertion;   Genetic: Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells;   Drug: Fludarabine
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Stanford University;   Juno Therapeutics, Inc.
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Brain Neoplasm;   Recurrent Malignant Solid Neoplasm;   Refractory Brain Neoplasm
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Temsirolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: rivogenlecleucel & rimiducid;   Drug: rimiducid;   Drug: Cyclophosphamide
    Sponsor:   Bellicum Pharmaceuticals
    Recruiting

  • Conditions:   Recurrent Hepatocellular Carcinoma;   Refractory Liver Carcinoma;   Stage IV Hepatocellular Carcinoma AJCC v8;   Stage IVA Hepatocellular Carcinoma AJCC v8;   Stage IVB Hepatocellular Carcinoma AJCC v8
    Interventions:   Drug: Cyclophosphamide;   Biological: IRX-2;   Biological: Nivolumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Rhabdoid Tumor;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Germ Cell Tumors;   Ewings Sarcoma;   Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
    Interventions:   Drug: Simvastatin;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Myeloid growth factor
    Sponsors:   Emory University;   Children's Healthcare of Atlanta
    Recruiting

  • Conditions:   Glioblastoma;   Gliosarcoma
    Interventions:   Drug: ERC1671;   Drug: GM-CSF;   Drug: Cyclophosphamide;   Drug: Oral Control (Sucrose pill);   Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%));   Drug: Bevacizumab
    Sponsors:   Daniela A. Bota;   University of California, Irvine;   Epitopoietic Research Corporation
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Ependymoma;   Childhood Atypical Teratoid/Rhabdoid Tumor;   Embryonal Tumor With Abundant Neuropil and True Rosettes;   Metastatic Malignant Neoplasm to the Leptomeninges
    Interventions:   Drug: Intra thecal methotrexate;   Drug: topotecan;   Drug: cyclophosphamide
    Sponsor:   Nicklaus Children's Hospital f/k/a Miami Children's Hospital
    Recruiting

  • Conditions:   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Metastatic Gastric Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Recurrent Gastric Adenocarcinoma;   Recurrent Gastroesophageal Junction Adenocarcinoma
    Interventions:   Drug: Cyclophosphamide;   Biological: IRX-2;   Biological: Pembrolizumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hematological Malignancy
    Intervention:   Drug: Bortezomib
    Sponsor:   Henry Ford Health System
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CAR-T Cells
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Other: Haploidentical Stem Cell Transplantation
    Sponsor:   Loyola University
    Recruiting

  • Conditions:   Malignant Glioma of Brain;   Astrocytoma;   Malignant Astrocytoma;   Oligodendroglioma;   Anaplastic Oligodendroglioma of Brain (Diagnosis);   Mixed Oligo-Astrocytoma;   Ependymoma;   Ganglioglioma;   Pylocytic/Pylomyxoid Astrocytoma;   Brain Tumor;   Glioma;   Brain Cancer;   Glioblastoma;   Glioblastoma Multiforme
    Interventions:   Drug: rQNestin;   Drug: Cyclophosphamide;   Procedure: Stereotactic biopsy
    Sponsors:   Dana-Farber Cancer Institute;   National Institutes of Health (NIH);   Advantagene, Inc.
    Recruiting

  • Conditions:   Solid Tumors;   Advanced Triple Negative Breast Cancer;   Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer;   Advanced Metastatic Castration-Resistant Prostate Cancer;   Advanced Platinum-Resistant Ovarian Cancer
    Interventions:   Drug: TRX518;   Drug: Cyclophosphamide;   Drug: Avelumab
    Sponsors:   Leap Therapeutics, Inc.;   Pfizer;   Merck KGaA, Darmstadt, Germany
    Recruiting

  • Condition:   X-Linked Chronic Granulomatious Disease
    Interventions:   Drug: Campath;   Drug: Busulfan;   Other: allogeneic peripheral blood allograft infusion;   Drug: cyclophosphamide
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   HLA-A*24:02 Positive Cells Present;   Metastatic Uveal Melanoma;   Uveal Melanoma Metastatic in the Liver
    Interventions:   Biological: Aldesleukin;   Biological: Autologous CD8+ SLC45A2-specific T Lymphocytes;   Drug: Cyclophosphamide;   Biological: Ipilimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Amyloidosis;   Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Gene Mutations;   Aplastic Anemia;   B-Cell Non-Hodgkin Lymphoma;   CD40 Ligand Deficiency;   Chronic Granulomatous Disease;   Chronic Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Congenital Amegakaryocytic Thrombocytopenia;   Congenital Neutropenia;   Congenital Pure Red Cell Aplasia;   Glanzmann Thrombasthenia;   Immunodeficiency Syndrome;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Plasma Cell Myeloma;   Polycythemia Vera;   Recurrent Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Severe Aplastic Anemia;   Shwachman-Diamond Syndrome;   Sickle Cell Disease;   T-Cell Non-Hodgkin Lymphoma;   Thalassemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Rabbit ATG
    Sponsor:   Northside Hospital, Inc.
    Recruiting

  • Conditions:   Anemia;   ASXL1 Gene Mutation;   EZH2 Gene Mutation;   IDH1 Gene Mutation;   IDH2 Gene Mutation;   Plasma Cell Myeloma;   Primary Myelofibrosis;   Recurrent Plasma Cell Myeloma;   Secondary Myelofibrosis;   Thrombocytopenia
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   University of Utah
    Recruiting

  • Conditions:   Inflammatory Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    Interventions:   Drug: Eribulin;   Drug: Adriamycin;   Drug: Cyclophosphamide
    Sponsors:   Dana-Farber Cancer Institute;   Eisai Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Relapsed Non Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Intervention:   Radiation: Total body irradiation
    Sponsor:   Loyola University
    Recruiting

  • Condition:   Adult Solid Neoplasm
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MV-NIS
    Sponsor:   University of Arkansas
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: EAGD T-cell infusion (Phase I);   Drug: EAGD T-cell infusion (Expansion)
    Sponsors:   University of Alabama at Birmingham;   Incysus
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Peripheral Blood White Cells;   CD19 Positive;   Chronic Lymphocytic Leukemia;   Minimal Residual Disease;   Non-Hodgkin Lymphoma;   Small Lymphocytic Lymphoma
    Interventions:   Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   M.D. Anderson Cancer Center;   Ziopharm Oncology;   Precigen, Inc
    Not yet recruiting

  • Conditions:   Non-myeloablative TCR Alpha/Beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation;   Recurrent Lip and Oral Cavity Carcinoma;   Recurrent Malignant Endocrine Neoplasm;   Recurrent Malignant Female Reproductive System Neoplasm;   Recurrent Malignant Male Reproductive System Neoplasm;   Recurrent Malignant Mesothelioma;   Recurrent Malignant Neoplasm of Multiple Primary Sites;   Recurrent Malignant Oral Neoplasm;   Recurrent Malignant Pharyngeal Neoplasm;   Recurrent Malignant Skin Neoplasm;   Recurrent Malignant Soft Tissue Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Malignant Thyroid Gland Neoplasm;   Recurrent Malignant Urinary System Neoplasm;   Recurrent Melanoma of the Skin;   Refractory Cutaneous Melanoma;   Refractory Malignant Bone Neoplasm;   Refractory Malignant Endocrine Neoplasm;   Refractory Malignant Female Reproductive System Neoplasm;   Refractory Malignant Male Reproductive System Neoplasm;   Refractory Malignant Mesothelioma;   Refractory Malignant Neoplasm of Multiple Primary Sites;   Refractory Malignant Oral Neoplasm;   Refractory Malignant Pharyngeal Neoplasm;   Refractory Malignant Skin Neoplasm;   Refractory Malignant Soft Tissue Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Malignant Thyroid Gland Neoplasm;   Refractory Malignant Urinary System Neoplasm
    Interventions:   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Philadelphia Chromosome Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B-Lymphoid Malignancies;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Non-hodgkin Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells;   Drug: AP1903
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Procedure: Therapeutic Conventional Surgery;   Drug: Triciribine Phosphate
    Sponsors:   Prescient Therapeutics, Ltd.;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Busulfan;   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Sirolimus;   Radiation: Total Body Irradiation;   Biological: Allogeneic peripheral blood stem cell
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting

  • Conditions:   HER2 Positive Breast Carcinoma;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Trastuzumab
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Immunoglobulin Heavy Chain Locus Variable Region Mutation;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: GVAX;   Drug: Pembrolizumab;   Drug: IMC-CS4
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Merck Sharp & Dohme Corp.;   Eli Lilly and Company
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer;   Hematologic Malignancies
    Intervention:   Biological: TAPA-pulsed DC vaccine
    Sponsor:   Kiromic, Inc.
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Gastric Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Sarcoma;   Mesothelioma;   Neuroendocrine Tumors;   Squamous Cell Cancer;   Merkel Cell Carcinoma;   Mismatch Repair Deficiency;   Microsatellite Instability
    Interventions:   Biological: Tumor Infiltrating Lymphocytes (TIL);   Drug: Fludarabine + Cyclophosphamide combination
    Sponsor:   Udai Kammula
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia, in Relapse;   Acute Myeloid Leukemia, Adult;   Acute Myeloid Leukemia, Refractory
    Intervention:   Biological: CART123 cells; cyclophosphamide; fludarabine
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
    Interventions:   Drug: etoposide;   Drug: cyclophosphamide;   Radiation: total marrow irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphocytic Leukemia;   Lymphoma
    Interventions:   Biological: Biological/Genetically Modified T cells;   Drug: Cyclophosphamide-based chemotherapy
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Genetic: GINAKIT Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital
    Recruiting

  • Condition:   Recurrent Primary Amyloidosis
    Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Biological: Elotuzumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI);   Bristol-Myers Squibb;   Multiple Myeloma Research Consortium
    Recruiting

  • Conditions:   Severe Aplastic Anemia (SAA);   Hypo-Plastic Myelodysplastic Syndrome (MDS)
    Intervention:   Procedure: haplo-identical transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Ovarian Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Bladder Cancer;   Microsatellite Instability-High
    Interventions:   Other: DPX-Survivac;   Drug: Cyclophosphamide;   Drug: Pembrolizumab
    Sponsors:   ImmunoVaccine Technologies, Inc. (IMV Inc.);   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Malignant Neoplasm of Breast
    Interventions:   Procedure: Breast Core Biopsy;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Panitumumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mammogram;   Procedure: Ultrasound;   Other: Follow Up
    Sponsors:   M.D. Anderson Cancer Center;   Amgen
    Recruiting

  • Conditions:   Myeloma-Multiple;   Myeloma, Plasma-Cell
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Anti-BCMA CAR T cells
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Intervention:   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Viragh Foundation
    Recruiting

  • Conditions:   Lymphoma, Large-Cell, Anaplasitc;   Hodgkin Disease;   Lymphoma, Hodgkins;   Enteropathy-Associated T-Cell Lymphoma;   Lymphoma, Extranodal NK-T-Cell
    Interventions:   Biological: Anti-CD30-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Radiation: Radiation;   Drug: Cyclophosphamide;   Biological: Donor Lymphocyte Infusion (DLI);   Biological: Haploidentical Stem Cell Transplantation
    Sponsors:   Northwell Health;   New York Blood Center
    Recruiting

  • Conditions:   Relapsed Neuroblastoma;   Refractory Neuroblastoma
    Interventions:   Genetic: C7R-GD2.CART cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Conditions:   Hematopoietic/Lymphoid Cancer;   Acute Myeloid Leukemia
    Interventions:   Procedure: Leukapheresis;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: CD33-CAR-T Cell Infusion
    Sponsors:   M.D. Anderson Cancer Center;   Intrexon Corporation;   Ziopharm
    Recruiting

  • Condition:   Hepatocellular Carcinoma
    Interventions:   Genetic: GLYCAR T cells;   Drug: Cytoxan;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Nivolumab;   Drug: GVAX Pancreas Vaccine;   Radiation: Stereotactic Body Radiation (SBRT)
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
    Interventions:   Genetic: CAR T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting

  • Conditions:   Fanconi Anemia;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Anti-Thymocyte Globulin (Rabbit);   Device: The CliniMACS device;   Drug: G-CSF
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Pediatric Brain Tumor Consortium
    Recruiting

  • Condition:   Neoplasms
    Interventions:   Genetic: NY-ESO-1ᶜ²⁵⁹T cell;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   GlaxoSmithKline
    Recruiting

  • Condition:   Advanced or Unresectable Melanoma Progressing After PD1 Blockade
    Interventions:   Biological: ONCOS-102;   Drug: Cyclophosphamide;   Drug: Pembrolizumab
    Sponsor:   Targovax Oy
    Recruiting

  • Conditions:   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Small Lymphocytic Lymphoma;   Relapsed Adult ALL;   Relapsed CLL;   Relapsed Non Hodgkin Lymphoma
    Interventions:   Genetic: CD19.CAR-aNKT cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Not yet recruiting

  • Conditions:   Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma;   Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
    Interventions:   Drug: Cyclophosphamide;   Biological: IRX-2;   Biological: Nivolumab;   Procedure: Surgery
    Sponsors:   Emory University;   Bristol-Myers Squibb;   Brooklyn ImmunoTherapeutics, LLC
    Not yet recruiting

  • Condition:   Liver Cancer Pediatric
    Interventions:   Genetic: GAP T cells;   Drug: Cytoxan;   Drug: Fludara
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   Cancer Prevention Research Institute of Texas;   V Foundation;   Cookies for Kids' Cancer;   Curing Kids' Cancer Foundation
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: GVAX;   Drug: Pembrolizumab;   Radiation: SBRT
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Gemtuzumab Ozogamicin
    Sponsor:   New York Medical College
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
    Interventions:   Biological: MABEL CTLs;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Condition:   Breast Neoplasms
    Intervention:   Drug: MEDI4736
    Sponsor:   Yale University
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Biological: EGFRt/BCMA-41BBz CAR T cell;   Drug: Cyclophosphamide;   Drug: Lenalidomide.
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Juno Therapeutics, Inc.
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Ann Arbor Stage I Burkitt Lymphoma;   Ann Arbor Stage I Non-Hodgkin Lymphoma;   Ann Arbor Stage II Burkitt Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage III Burkitt Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Burkitt Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   High Risk Acute Myeloid Leukemia;   Progressive Disease;   Refractory Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myeloma-Multiple;   Myeloma, Plasma-Cell
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Rimiducid;   Biological: Anti-SLAMF7 CAR T cells
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Graft Failure;   Secondary Graft Failure
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Hematopoietic stem cell infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
    Interventions:   Drug: KITE-439;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Immune System Diseases;   Immunoproliferative Disorders
    Interventions:   Biological: iC9-CAR19 cells;   Drug: AP1903;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Condition:   Scleroderma, Systemic
    Interventions:   Biological: Peripheral Blood Stem Cells;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Fludarabine
    Sponsor:   Northwestern University
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Secondary Myelofibrosis;   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Blasts 15 Percent or Less of Bone Marrow Nucleated Cells;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
    Interventions:   Drug: Everolimus;   Drug: Nelarabine;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsor:   Emory University
    Recruiting

  • Conditions:   Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Lymphatic Diseases
    Interventions:   Drug: Brentuximab Vedotin;   Drug: CHEP
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Seattle Genetics, Inc.
    Recruiting

  • Condition:   Mantle-Cell Lymphoma
    Interventions:   Biological: G-CSF;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Vincristine
    Sponsor:   University of Miami
    Recruiting

  • Condition:   AL Amyloidosis
    Interventions:   Drug: Ixazomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Icahn School of Medicine at Mount Sinai;   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Sarcoma
    Interventions:   Genetic: Autologous HER2-specific T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Conditions:   Glioblastoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Individual Patient TCR-Transduced PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   SLAMF7 Positive
    Interventions:   Procedure: CS1-CAR T Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Leukapheresis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
    Interventions:   Biological: CD19 CAR T Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Conditions:   Melanoma;   Meningioma;   Breast Cancer;   Non-Small Cell Lung Cancer;   Hepatocellular Cancer
    Interventions:   Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoid Leukemia;   B-Cell Leukemia;   Leukemia, Lymphocytic, B Cell;   B-Cell Lymphoma;   Lymphoma, Non-Hodgkin
    Interventions:   Biological: CD19/CD22 CAR T-Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Cyclophosphamide;   Drug: Carboplatin
    Sponsors:   Dana-Farber Cancer Institute;   Mayo Clinic
    Recruiting

  • Condition:   Prostate Cancer
    Interventions:   Biological: CART T cells;   Drug: Cyclophosphamide 1g/m^2
    Sponsor:   University of Pennsylvania
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Busulfan;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: GVAX Pancreas Vaccine;   Drug: CRS-207
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Aduro Biotech, Inc.;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Graft Versus Host Disease;   Hematologic Neoplasms
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Pancreatic Cancer;   Gastric Cancer;   Gastrointestinal Cancer;   Colon Cancer;   Rectal Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: anti-KRAS G12V mTCR;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Renal Cell Cancer;   Breast Cancer;   Melanoma;   Ovarian Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Anti-hCD70 CAR transduced PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Synovial Sarcoma;   Myxoid Liposarcoma;   HLA-A*0201 Positive Cells Present;   NY-ESO-1 Positive Tumor Cells Present;   Recurrent Myxoid Liposarcoma;   Recurrent Synovial Sarcoma
    Interventions:   Biological: Aldesleukin;   Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes;   Drug: Cyclophosphamide;   Biological: Dendritic Cell-targeting Lentiviral Vector ID-LV305;   Drug: Immunotherapeutic Combination Product CMB305
    Sponsors:   M.D. Anderson Cancer Center;   Immune Design;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cervical Cancer;   Renal Cancer;   Urothelial Cancer;   Melanoma;   Breast Cancer
    Interventions:   Biological: Anti-MAGE-A3-DP4 TCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: high dose Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Osteosarcoma;   Neuroblastoma
    Interventions:   Genetic: GD2 T cells;   Biological: VZV vaccine;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI);   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting

  • Conditions:   Gastrointestinal Cancer;   Pancreatic Cancer;   Gastric Cancer;   Colon Cancer;   Rectal Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: anti-KRAS G12D mTCR PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Immunodeficiency Syndrome;   Non-Cancer Diagnosis;   Severe Aplastic Anemia;   Donor
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   CD19 Positive;   Minimal Residual Disease;   Non-Hodgkin Lymphoma;   Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Tisagenlecleucel
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   PSA Progression;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   PSCA Positive
    Interventions:   Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Biological: iC9.GD2.CAR.IL-15 T-cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Conditions:   Mesothelioma;   Mesothelioma, Malignant;   Mesothelioma; Pleura;   Mesotheliomas Pleural;   Mesothelioma Peritoneum;   Cholangiocarcinoma;   Cholangiocarcinoma Recurrent;   Ovarian Cancer;   Non Small Cell Lung Cancer;   Non Small Cell Lung Cancer Metastatic
    Interventions:   Drug: TC-210 T Cells;   Drug: fludarabine;   Drug: cyclophosphamide;   Biological: anti-PD1
    Sponsor:   TCR2 Therapeutics
    Recruiting

  • Conditions:   Advanced Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma;   Advanced NSCLC;   Adenosquamous Carcinoma;   Adenocarcinomas
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   T-cell Acute Lymphoblastic Leukemia;   T-cell Acute Lymphoblastic Lymphoma;   T-non-Hodgkin Lymphoma
    Interventions:   Genetic: CD7.CAR/28zeta CAR T cells;   Drug: Fludarabine;   Drug: Cytoxan
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Not yet recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Donor;   Lymphoblastic Lymphoma;   Mixed Phenotype Acute Leukemia
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Tacrolimus;   Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs;   Drug: Methotrexate;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells;   Drug: Peripheral Blood Stem Cell
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Lung Adenocarcinoma;   Ovarian Cancer;   Peritoneal Carcinoma;   Fallopian Tube Cancer;   Mesotheliomas Pleural;   Mesothelioma Peritoneum
    Intervention:   Biological: huCART-meso cells
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Recurrent Transformed B-cell Non-Hodgkin Lymphoma;   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Marginal Zone Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma;   Refractory Transformed Chronic Lymphocytic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   TNFRSF17 Positive
    Interventions:   Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Juno Therapeutics, Inc.;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Liver Transplant
    Interventions:   Biological: arTreg;   Procedure: leukapheresis;   Drug: cyclophosphamide;   Drug: mesna;   Drug: everolimus
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Not yet recruiting

  • Condition:   Metastatic Pancreatic Adenocarcinoma
    Interventions:   Drug: Epacadostat;   Drug: Pembrolizumab;   Biological: CRS-207;   Drug: CY;   Biological: GVAX
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Liver Transplant
    Interventions:   Biological: arTreg-CSB;   Procedure: leukapheresis;   Drug: cyclophosphamide;   Drug: mesna;   Drug: everolimus
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Crystal Mackall, MD;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Crystal Mackall, MD;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Decitabine;   Biological: Genetically Engineered NY-ESO-1-specific T Lymphocytes;   Other: Laboratory Biomarker Analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   T-cell Acute Lymphoblastic Lymphoma;   T-non-Hodgkin Lymphoma;   T-cell Acute Lymphoblastic Leukemia
    Interventions:   Genetic: CD5.CAR/28zeta CAR T cells;   Drug: Fludarabine;   Drug: Cytoxan
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Biological: BCMA-specific CAR-expressing T Lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Gamma-Secretase Inhibitor LY3039478;   Other: Laboratory Biomarker Analysis;   Other: Pharmacokinetic Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   MYC Gene Rearrangement;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma
    Interventions:   Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Biological: GVAX pancreatic cancer;   Drug: Nivolumab;   Drug: Urelumab
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI);   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Neuroblastoma;   High-Risk
    Interventions:   Drug: cyclophosphamide;   Biological: NK cells;   Biological: hu3F8;   Drug: rIL-2
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Y-mAbs Therapeutics
    Recruiting

  • Conditions:   Adult Acute Myeloid Leukemia in Remission;   Acute Biphenotypic Leukemia;   Early Relapse of Acute Myeloid Leukemia;   Late Relapse of Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Acute Myeloid Leukemia;   Adult Acute Lymphoblastic Leukemia;   Interleukin-3 Receptor Subunit Alpha Positive;   Minimal Residual Disease;   Refractory Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: cyclophosphamide;   Biological: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes;   Other: laboratory biomarker analysis;   Biological: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes;   Drug: Fludarabine Phosphate
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI);   Mustang Bio, Inc.
    Recruiting

  • Conditions:   Burkitt Leukemia;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Burkitt Leukemia;   Recurrent Burkitt Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Acute Lymphoblastic Leukemia;   Refractory Burkitt Leukemia;   Refractory Burkitt Lymphoma;   Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Lymphoblastic Lymphoma
    Interventions:   Drug: Bortezomib;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Etoposide;   Biological: Ofatumumab;   Biological: Pegfilgrastim;   Biological: Rituximab;   Drug: Vincristine Sulfate Liposome
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Melanoma
    Interventions:   Biological: Mature dendritic cell (DC) vaccine;   Drug: Cyclophosphamide 300mg/m^2;   Drug: Pembrolizumab
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent T Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia;   Refractory T Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Nelarabine;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
    Interventions:   Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Multiple Myeloma;   Melanoma;   Synovial Sarcoma;   Myxoid/Round Cell Liposarcoma
    Interventions:   Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Device: NY-ESO-1 expression testing
    Sponsors:   University of Pennsylvania;   Parker Institute for Cancer Immunotherapy;   Tmunity Therapeutics Inc.
    Recruiting

  • Condition:   Locally Advanced Breast Cancer
    Interventions:   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Pegfilgrastim;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsor:   Icahn School of Medicine at Mount Sinai
    Recruiting

  • Conditions:   Colorectal Adenocarcinoma;   Metastatic Cholangiocarcinoma;   Metastatic Colorectal Carcinoma;   Metastatic Digestive System Carcinoma;   Metastatic Esophageal Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Pancreatic Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IV Esophageal Cancer AJCC v7;   Stage IV Gastric Cancer AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Biological: Adoptive Immunotherapy;   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center;   Fred Hutchinson Cancer Research Center
    Recruiting

  • Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Mantle-Cell Lymphoma;   Follicular Lymphoma;   Indolent B Cell Lymphoma;   Primary Mediastinal Lymphoma;   Lymphoplasmacytic Lymphoma
    Intervention:   Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia, in Relapse;   Acute Lymphoblastic Leukemia, Refractory
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Mesna;   Device: CliniMACS;   Biological: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   COL6A3 Positive;   HLA-A*0201 Positive Cells Present;   PRAME Positive;   Recurrent Ovarian Carcinoma
    Interventions:   Biological: Aldesleukin;   Drug: CD8-Positive T-Lymphocyte;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Utomilumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   High Grade Ovarian Serous Adenocarcinoma;   Oligometastasis;   Ovarian Carcinosarcoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Osteosarcoma;   Recurrent Ovarian Carcinoma;   Refractory Osteosarcoma;   Refractory Ovarian Carcinoma
    Interventions:   Biological: Autologous Tumor Infiltrating Lymphocytes MDA-TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Interleukin-2;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb;   Iovance Biotherapeutics, Inc.
    Recruiting

  • Conditions:   Breast Adenocarcinoma;   Estrogen Receptor- Negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Progesterone Receptor Positive Tumor;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Triple-negative Breast Carcinoma
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Decitabine;   Drug: Pembrolizumab
    Sponsors:   Virginia Commonwealth University;   Merck Sharp & Dohme Corp.;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Nivolumab 360 mg+ paclitaxel 80 mg/m2;   Drug: Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2;   Drug: Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg;   Drug: Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2
    Sponsor:   NYU Langone Health
    Not yet recruiting

  • Conditions:   Cervical Squamous Cell Carcinoma In Situ;   Vulvar High Grade Squamous Intraepithelial Lesion
    Interventions:   Drug: Cyclophosphamide;   Drug: Indomethacin;   Biological: IRX-2;   Other: Laboratory Biomarker Analysis;   Dietary Supplement: Multivitamin;   Drug: Omeprazole;   Other: Placebo;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldeslaukin;   Drug: Pembrolizumab;   Biological: young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Radiation: total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Clofarabine;   Procedure: (CliniMACS) T-cell depleted PBSC Transplant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Rituximab;   Drug: Melphalan;   Drug: Fludarabine;   Radiation: Total body irradiation (TBI);   Procedure: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Metastatic Non-small Cell Lung Cancer;   Squamous Cell Carcinoma;   Advanced NSCLC;   Adenosquamous Carcinoma;   Adenocarcinomas
    Interventions:   Procedure: Tumor-infiltrating Lymphocytes (TIL);   Drug: Nivolumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Tumor-infiltrating Lymphocyte Therapy;   Drug: Interleukin-2 (IL2)
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb;   Prometheus Inc.;   Stand Up To Cancer;   Iovance Biotherapeutics, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   B-cell Acute Lymphoblastic Leukemia
    Interventions:   Genetic: PBCAR0191;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Precision BioSciences, Inc.
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure;   Immunosuppression
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Brentuximab vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone
    Sponsors:   Patrick Reagan;   Seattle Genetics, Inc.
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Bone Sarcoma;   Dedifferentiated Chondrosarcoma;   Giant Cell Tumor of Bone;   Malignancy in Giant Cell Tumor of Bone;   Ovarian Carcinosarcoma;   Platinum-Resistant Ovarian Carcinoma;   Recurrent Osteosarcoma;   Refractory Osteosarcoma;   Refractory Ovarian Carcinoma;   Soft Tissue Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
    Interventions:   Biological: Aldesleukin;   Biological: Autologous Tumor Infiltrating Lymphocytes LN-145;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Stem Cell Transplant;   Drug: Anti-thymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Refractory and/or Relapsed Metastatic Solid Tumors
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: low dose total body irradiation;   Drug: Melphalan;   Drug: Tacrolimus
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer;   Solid Tumor
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: IMA101 product;   Biological: Recombinant human interleukin-2;   Diagnostic Test: IMADetect;   Drug: Atezolizumab
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Metastatic Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: NGFR-transduced Autologous T Lymphocytes;   Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Tumor Infiltrating Lymphocytes;   Drug: Nivolumab and Ipilimumab
    Sponsor:   Yale University
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI);   Janssen Scientific Affairs, LLC
    Recruiting

  • Conditions:   Leukemia;   MDS;   Myelofibrosis;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation;   Other: Hematopoietic stem cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate;   Drug: G-CSF
    Sponsor:   Rafic Farah, MD
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Bone Marrow Failure;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Follicular Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia;   Non-Hodgkin Lymphoma;   Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Cytokine-treated Veto Cells;   Drug: Fludarabine;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Metastatic Colorectal Cancer;   Progressive Glioblastoma;   Metastatic Pancreatic Cancer;   Metastatic Ovarian Cancer;   Metastatic Breast Cancer
    Interventions:   Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Pembrolizumab (Keytruda)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Sclerosis, Relapsing-Remitting
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: G-CSF;   Biological: IVIg;   Biological: Autologous Stem Cells
    Sponsor:   Northwestern University
    Recruiting

  • Conditions:   Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Procedure: Radiotherapy
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia;   Myeloproliferative Disorder;   Myelofibrosis;   Lymphoma;   Lymphoma, Non-Hodgkin;   Plasma Cell Disorder
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Drug: Tacrolimus;   Drug: cellcept;   Drug: g-csf;   Procedure: Peripheral Blood Transplant
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Post-transplant Lymphoproliferative Disorder;   B-Cell Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma
    Interventions:   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Drug: Bendamustine Hydrochloride;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Diffuse Intrinsic Pontine Glioma (DIPG)
    Interventions:   Biological: TTRNA-DC vaccines with GM-CSF;   Biological: TTRNA-xALT;   Drug: Cyclophosphamide + Fludarabine Lymphodepletive Conditioning;   Drug: Dose-Intensified TMZ;   Drug: Td vaccine;   Biological: Autologous Hematopoietic Stem Cells (HSC)
    Sponsors:   University of Florida;   Accelerate Brain Cancer Cure;   Lyla Nsouli Foundation
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Sirolimus;   Drug: Fludarabine;   Radiation: Total body irradiation;   Procedure: Hematopoietic stem cell transplant
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Biological: Palifermin;   Biological: Lupron;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total-Body Irradiation (TBI);   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Degarelix
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Swedish Orphan Biovitrum
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Combination Product: BCMA CART + huCART19;   Combination Product: CART BCMA or CART BCMA + huCART19;   Combination Product: Single-dose infusion of CART BCMA or CART BCMA + huCART19
    Sponsors:   University of Pennsylvania;   Novartis
    Recruiting

  • Conditions:   HLA-A2 Positive Cells Present;   Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
    Interventions:   Biological: Aldesleukin;   Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Albert Einstein College of Medicine;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Thalassemia;   High Risk Hematologic Disorders;   Cerebral Adrenoleukodystrophy;   Inherited Metabolic Disorders
    Intervention:   Procedure: Blood and Marrow Transplant
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
    Interventions:   Drug: MOv19-BBz CAR T cells;   Device: Alpha Folate Receptor expression test
    Sponsor:   University of Pennsylvania
    Recruiting

  • Condition:   Hematologic Malignancy
    Interventions:   Drug: melphalan;   Drug: fludarabine;   Drug: thiotepa;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Mycophenolate Mofetil;   Drug: Filgrastim;   Drug: Tacrolimus
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Recurrent or Refractory Solid Tumors;   Ewing Sarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Osteosarcoma
    Intervention:   Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
    Sponsor:   South Plains Oncology Consortium
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Melphalan;   Drug: Etoposide;   Drug: Carboplatin;   Biological: Autologous Stem Cell Infusion;   Biological: Granulocyte colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Lymphoid Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML);   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Radiation: Hyperfractionated total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Clofarabine;   Procedure: HPC(A) stem cell allograft;   Drug: Rituximab;   Device: Rabbit antithymocyte globulin
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Drug: Etoposide;   Drug: BCNU;   Drug: AraC;   Drug: Melphalan;   Procedure: Peripheral blood stem cell transplantation;   Biological: G-CSF;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Myeloid Diseases
    Interventions:   Drug: Antithymocyte globulin (Rabbit);   Drug: fludarabine;   Radiation: total body irradiation;   Drug: cyclophosphamide;   Drug: Rituxan;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Biological: Rituximab;   Drug: Spleen Tyrosine Kinase Inhibitor TAK-659;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Aldesleukin;   Biological: CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: NGFR-transduced Autologous T Lymphocytes;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS);   NK-Cell Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma (NHL);   Juvenile Myelomonocytic Leukemia (JMML);   Chronic Myeloid Leukemia (CML)
    Interventions:   Drug: Cyclophosphamide;   Biological: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Biological: G-csf;   Drug: Mesna;   Device: CliniMACS;   Biological: ATG (rabbit);   Drug: Blinatumomab;   Biological: TCRα/β+;   Biological: CD19+;   Biological: CD45RA-depleted DLI
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Radiation: radiation therapy;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting

  • Conditions:   Diffuse Large B Cell Lymphoma;   DLBCL;   Cancer
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Biological: Pegfilgrastim
    Sponsors:   University of Wisconsin, Madison;   Medical College of Wisconsin
    Not yet recruiting

  • Condition:   Leukemia
    Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: bone marrow transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Cyclophosphamide;   Other: Cytology Specimen Collection Procedure;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Trastuzumab
    Sponsors:   Albert Einstein College of Medicine;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Papillomavirus Infections;   Cervical Intraepithelial Neoplasia;   Carcinoma In Situ;   Vulvar Neoplasms;   Vulvar Diseases
    Interventions:   Biological: E7 TCR cells;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: Mycophenolate mofetil
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting

  • Condition:   B-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS;   Drug: Sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Neuromyelitis Optica;   Devic's Disease;   NMO Spectrum Disorder
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: G-CSF;   Biological: IVIg;   Biological: Autologous Stem Cells
    Sponsor:   Northwestern University
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: ATG;   Drug: fludarabine;   Drug: cyclophosphamide;   Radiation: Total body irradiation;   Procedure: Stem cell infusion;   Drug: Sirolimus;   Drug: mycophenolate mofetil
    Sponsor:   University of Illinois at Chicago
    Recruiting

  • Conditions:   Sickle Cell Disease;   Sickle Cell Disorder;   Hemoglobinopathies;   Thalassemia;   Anemia, Sickle Cell
    Interventions:   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Rabbit anti-thymocyte globulin;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
    Sponsors:   City of Hope Medical Center;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Condition:   Bone Marrow Failure Syndromes
    Interventions:   Other: MRD-BMT with Fludarabine-based RIC for Acquired AA;   Other: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia;   Other: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Systemic Sclerosis;   Scleroderma
    Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: G-CSF;   Biological: IVIg;   Biological: Autologous Stem Cells
    Sponsor:   Northwestern University
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Lymphoma
    Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Composite Lymphoma;   Grade 3b Follicular Lymphoma;   Stage I Diffuse Large B-Cell Lymphoma;   Stage I Follicular Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage II Follicular Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage III Follicular Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma;   Stage IV Follicular Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Rituximab;   Drug: Blinatumomab
    Sponsors:   M.D. Anderson Cancer Center;   Amgen
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin;   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young Tumor Infiltrating Lymphocytes (Young TIL);   Drug: Pembrolizumab (Keytruda)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Indolent Non-Hodgkin Lymphoma;   Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Transformed Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Nivolumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Kami Maddocks;   National Cancer Institute (NCI);   Bristol-Myers Squibb
    Not yet recruiting

  • Condition:   Melanoma
    Interventions:   Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T-Cells;   Biological: Interleukin-2;   Drug: Mesna;   Biological: Intrathecal T-Cells;   Biological: Intrathecal Interleukin-2
    Sponsors:   M.D. Anderson Cancer Center;   Prometheus Laboratories;   Key Biologics, LLC;   National Cancer Institute (NCI);   Adelson Medical Research
    Recruiting

  • Condition:   Malignant Neoplasm
    Interventions:   Biological: aldesleukin;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL;   Biological: dendritic cell vaccine therapy;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography
    Sponsor:   Jonsson Comprehensive Cancer Center
    Recruiting

  • Conditions:   AIDS-Related Burkitt Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Burkitt Lymphoma;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Burkitt Lymphoma;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Ofatumumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Solid Neoplasm;   Childhood Solid Neoplasm;   Metastatic Neoplasm
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine;   Procedure: Positron Emission Tomography
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine;   Drug: Mycophenolate Mofetil;   Drug: Sorafenib;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Gene Mutations;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
    Sponsors:   Washington University School of Medicine;   National Institutes of Health (NIH);   The V Foundation for Cancer Research;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Hematological Disease;   Immune Deficiencies;   Solid Tumors;   Myelofibrosis;   Multiple Myeloma;   Lymphoma
    Interventions:   Radiation: Total Body Irradiation 1200 cGy;   Drug: Fludarabine;   Drug: Pre-Stem Cell Infusion Cyclophosphamide;   Drug: Pre-Stem Cell Infusion Mesna;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Drug: Post-Stem Cell Infusion Cyclophosphamide;   Drug: Post-Stem Cell Infusion Mesna;   Drug: Thiotepa
    Sponsor:   University of Rochester
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   HER2/Neu Positive;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IA Breast Cancer;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Relapsed/Refractory Large B Cell Lymphoma;   Relapsed/Refractory Follicular Lymphoma
    Interventions:   Genetic: ALLO-501;   Biological: ALLO-647;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Allogene Therapeutics
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Thalidomide;   Drug: Dexamethasone;   Drug: Daratumumab;   Drug: Cisplatin;   Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Melphalan;   Procedure: ASCT;   Drug: Lenalidomide;   Drug: Bortezomib
    Sponsors:   University of Arkansas;   Janssen, LP
    Recruiting

  • Conditions:   NK-Cell Lymphoma;   NK-Cell Leukemia;   Peripheral T Cell Lymphoma
    Interventions:   Drug: Methotrexate;   Drug: pralatraxate,;   Drug: Ifosfamide;   Drug: Dexamethasone;   Drug: Etoposide;   Drug: Pegaspargase;   Drug: cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Brentuximab Vedotin
    Sponsors:   New York Medical College;   University of Alabama at Birmingham
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   ERBB2 Gene Amplification;   Estrogen Receptor Positive;   Inflammatory Breast Carcinoma;   Metastatic Breast Carcinoma;   Progesterone Receptor Positive;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Neratinib;   Drug: Paclitaxel;   Biological: Pertuzumab;   Biological: Trastuzumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Puma Biotechnology, Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Idarubicin;   Drug: Idelalisib;   Device: In Vitro Kinase Inhibitor Assay;   Drug: Leucovorin Calcium;   Drug: Methotrexate;   Drug: Methylprednisolone Sodium Succinate;   Drug: Ponatinib Hydrochloride;   Biological: Rituximab;   Drug: Ruxolitinib Phosphate;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate;   Drug: Vincristine Sulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Cancer of the Pancreas
    Intervention:   Biological: huCART-meso cells
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Burkitt Lymphoma;   KSHV-associated Multicentric Castleman Disease;   Diffuse Large B-Cell Lymphoma
    Interventions:   Biological: Rituximab or Rituximab Hyaluronidase Human;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Drug: Etoposide
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Relapsed Solid Tumors;   Refractory Solid Tumors;   Leukemias
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsors:   Phoenix Children's Hospital;   Amgen;   Pediatric Oncology Experimental Therapeutics Investigators' Consortium
    Recruiting

  • Condition:   Crohn Disease
    Interventions:   Procedure: Autologous stem cell transplant;   Drug: Cyclophosphamide;   Drug: Thymoglobulin;   Drug: Methylprednisolone;   Drug: Vedolizumab
    Sponsor:   Icahn School of Medicine at Mount Sinai
    Recruiting

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: carfilzomib;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B-cell Lymphoma
    Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Amyloidosis
    Interventions:   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Dexamethasone, 40 mg;   Drug: Daratumumab
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Large B-cell Lymphoma
    Interventions:   Drug: KYMRIAH;   Drug: YESCARTA;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MEL-CFZ-TD-PACE
    Sponsors:   University of Arkansas;   Amgen
    Recruiting

  • Conditions:   Acute Leukemia;   Immune Deficiency Disorder;   Congenital Hematological Disorder;   Metabolism Disorder;   Aplastic Anemia;   Myelodysplastic Syndromes;   Chronic Leukemia;   Lymphoma;   Multiple Myeloma;   Solid Tumor
    Interventions:   Radiation: Total Body Irradiation 1200 cGy;   Radiation: Total Body Irradiation 200 cGy;   Drug: Cyclophosphamide;   Drug: Mesna;   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan
    Sponsor:   University of Rochester
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Juvenile Myelomonocytic Leukemia (JMML);   Acute Lymphoblastic Leukemia (ALL);   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome
    Interventions:   Biological: ATIR101;   Drug: Cyclophosphamide;   Procedure: T-cell depleted HSCT from a related, haploidentical donor;   Procedure: T-cell replete HSCT from a related, haploidentical donor
    Sponsor:   Kiadis Pharma
    Recruiting

  • Conditions:   GATA2;   Immunodeficiency;   MDS
    Interventions:   Procedure: Allogeneic HSC;   Drug: Busulfan Test dose;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Human Papillomavirus-Related Carcinoma;   Human Papillomavirus Positive Oropharyngeal Carcinoma;   Human Papillomavirus Positive Cervical Carcinoma;   Human Papillomavirus Positive Anal Carcinoma;   Human Papillomavirus Positive Vulvar Carcinoma;   Human Papillomavirus Positive Penile Carcinoma
    Interventions:   Genetic: HPV Specific T Cells;   Drug: Cytoxan;   Drug: Fludarabine;   Biological: Nivolumab
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System
    Recruiting

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Cytokine-induced killer cells;   Biological: IL-2;   Drug: ALT-803;   Procedure: Peripheral blood for correlative studies;   Procedure: Bone marrow for correlative studies
    Sponsors:   Washington University School of Medicine;   American Society of Clinical Oncology;   American Society of Hematology;   Gabrielle's Angel Foundation;   The Leukemia and Lymphoma Society;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Angioimmunoblastic T-Cell Lymphoma;   CD30-Positive Neoplastic Cells Present;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Stage III Anaplastic Large Cell Lymphoma;   Stage IV Anaplastic Large Cell Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD20 Positive;   Mantle Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Ibrutinib;   Drug: Methotrexate;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Acute Myeloid Leukemia With Variant MLL Translocations;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Chemotherapy-Related Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Gene Mutation;   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Allogeneic Natural Killer Cell Line NK-92;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   B-Cell Non-Hodgkin Lymphoma;   CD20 Positive;   Diffuse Large B-Cell Lymphoma Unclassifiable;   Intravascular Large B-Cell Lymphoma;   Primary Mediastinal (Thymic) Large B-Cell Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Biological: Nivolumab;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   Bristol-Myers Squibb (BMS);   National Cancer Institute (NCI)
    Recruiting

  • Condition:   DLBCL
    Interventions:   Drug: Rituximab Prednisone;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   University of Rochester
    Recruiting

  • Condition:   Squamous Cell Carcinoma of the Oral Cavity
    Interventions:   Drug: GL-0817;   Drug: Hiltonol;   Drug: Sargramostim;   Drug: cyclophosphamide;   Drug: Placebo
    Sponsor:   Gliknik Inc.
    Recruiting

  • Conditions:   Systemic Sclerosis;   Diffuse Sclerosis Systemic;   Interstitial Lung Disease;   Pulmonary Hypertension
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Thiotepa;   Drug: GM-CSF;   Drug: Intravenous immunoglobulin;   Radiation: Total Body Irradiation
    Sponsor:   Paul Szabolcs
    Recruiting

  • Condition:   DOCK8 Deficiency
    Interventions:   Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Busulfan (Busulfex);   Procedure: Donor peripheral blood stem cell mobiliation and collection;   Procedure: Bone Marrow Harvest Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   AML;   MDS
    Intervention:   Biological: NKR-2
    Sponsors:   Celyad (formerly named Cardio3 BioSciences);   Novella Clinical
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Donor;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Refractory Large B-cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Axicabtagene Ciloleucel;   Biological: Utomilumab
    Sponsors:   Kite, A Gilead Company;   Pfizer
    Recruiting

  • Condition:   Metastatic Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: Aldoxorubicin HCl;   Biological: ALT-803;   Biological: ETBX-011;   Biological: ETBX-021;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-4000;   Biological: GI-6207;   Biological: GI-6301;   Biological: haNK;   Drug: Avelumab;   Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Cyclophosphamide;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin
    Sponsor:   NantKwest, Inc.
    Not yet recruiting

  • Conditions:   Breast Cancer Female;   Breast Neoplasm Female
    Interventions:   Biological: SV-BR-1-GM;   Biological: Pembrolizumab;   Drug: Low dose cyclophosphamide;   Biological: Interferon Inoculation
    Sponsors:   BriaCell Therapeutics Corporation;   Cancer Insight, LLC
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: bendamustine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Bleomycin;   Drug: Vincristine;   Drug: Vinblastine;   Drug: Prednisone;   Drug: Filgrastim;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: DTIC;   Other: Quality of Life Measurements;   Radiation: Radiotherapy
    Sponsors:   St. Jude Children's Research Hospital;   Teva Pharmaceuticals USA;   Seattle Genetics, Inc.
    Recruiting

  • Conditions:   Bilateral Breast Carcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma;   Unilateral Breast Carcinoma
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine;   Other: Placebo;   Biological: Sargramostim
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Epithelial Ovarian Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Peritoneal Cancer
    Interventions:   Other: DPX-Survivac;   Drug: Cyclophosphamide;   Drug: Epacadostat (INCB024360)
    Sponsors:   ImmunoVaccine Technologies, Inc. (IMV Inc.);   Incyte Corporation
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Placebo;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Trastuzumab Emtansine
    Sponsors:   Hoffmann-La Roche;   Chugai Pharmaceutical
    Recruiting

  • Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Lymphoma;   Peripheral T-cell Lymphoma
    Interventions:   Drug: Temsirolimus;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Hydrocortisone;   Drug: Cytarabine
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Pfizer
    Recruiting

  • Conditions:   Malignant Pleural Disease;   Mesothelioma;   Metastases;   Lung Cancer;   Breast Cancer
    Interventions:   Genetic: iCasp9M28z T cell infusions;   Drug: cyclophosphamide;   Drug: pembrolizumab
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   MYC Gene Rearrangement;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Interventions:   Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014;   Drug: Cyclophosphamide;   Biological: Durvalumab;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   AstraZeneca;   Juno Therapeutics, Inc.;   MedImmune LLC;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Retinoblastoma
    Interventions:   Drug: vincristine;   Drug: topotecan;   Drug: filgrastim;   Drug: PEG-filgrastim;   Drug: carboplatin;   Other: focal therapy;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: MESNA;   Drug: doxorubicin;   Procedure: enucleation;   Radiation: external beam radiation or proton beam radiation
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor;   Ependymoma;   Medulloblastoma;   Diffuse Intrinsic Pontine Glioma;   Primary CNS Tumor
    Interventions:   Drug: Indoximod;   Drug: Temozolomide;   Radiation: Conformal Radiation;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsor:   NewLink Genetics Corporation
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Biological: Descartes-08;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Cartesian Therapeutics
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   B-Cell Lymphoma;   Non-Hodgkin Lymphoma
    Interventions:   Drug: RO7082859;   Drug: Obinutuzumab (G);   Drug: Rituximab (R);   Drug: Tocilizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Lymphoma
    Interventions:   Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: Pegaspargase;   Drug: Erwinase®;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Blinatumomab;   Drug: Ruxolitinib;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Clofarabine;   Drug: Vorinostat;   Drug: Idarubicin;   Drug: Nelarabine
    Sponsors:   St. Jude Children's Research Hospital;   Bristol-Myers Squibb;   Incyte Corporation;   Shire
    Recruiting

  • Conditions:   Primary Effusion Lymphoma;   B-Cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etopside;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
    Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Procedure: Bone Marrow Transplant (BMT);   Procedure: Bone Marrow Harvest (Donation);   Drug: Hydroxyurea;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Other: Rabbit Anti-thymocyte Globulin;   Radiation: Total Body Irradiation
    Sponsor:   Emory University
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Lorlatinib;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   Pfizer;   University of Southern California;   Solving Kids' Cancer US/EU;   Children's Neuroblastoma Cancer Foundation;   The Band of Parents;   The Evan Foundation;   Wade's Army;   Ronan Thompson Foundation;   The Catherine Elizabeth Blair Memorial Foundation;   Cookies for Kids' Cancer
    Recruiting

  • Conditions:   Breast Cancer;   Metastatic HER2-negative Breast
    Interventions:   Drug: Cyclophosphamide;   Biological: Mesothelin-targeted T cells;   Drug: AP1903
    Sponsors:   Memorial Sloan Kettering Cancer Center;   United States Department of Defense
    Recruiting

  • Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: Nab-paclitaxel;   Drug: Cisplatin;   Drug: 5Fluorouracil;   Drug: Cyclophosphamide;   Biological: ETBX-011;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-4000;   Biological: GI-6301;   Drug: Aldoxorubicin;   Drug: Avelumab;   Drug: ALT-803;   Biological: haNK;   Drug: Docetaxel;   Drug: carboplatin
    Sponsor:   NantKwest, Inc.
    Not yet recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: paclitaxel;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Carboplatin;   Procedure: Breast surgery;   Drug: AC
    Sponsors:   William Sikov MD;   Women and Infants Hospital of Rhode Island;   Rhode Island Hospital;   The Miriam Hospital
    Recruiting

  • Conditions:   Fanconi Anemia;   Severe Aplastic Anemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Total Body Irradiation (TBI) (Plan 1);   Drug: Cyclophosphamide (CY) (Plan 1);   Drug: Fludarabine (FLU);   Drug: Methylprednisolone (MP);   Device: Donor mobilized PBSC infusion;   Drug: G-CSF;   Drug: Cyclophosphamide (CY) (Plan 2);   Drug: Rituximab
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Lymphoproliferative Disorder;   HHV-8;   Malignancy;   HIV
    Interventions:   Drug: Etoposide;   Drug: Interferon-alpha;   Drug: Rituximab;   Drug: Zidovudine;   Drug: Liposomal Doxorubicin;   Drug: Bortezomib;   Drug: Valganciclovir;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Filgrastim (G-CSF);   Drug: Prednisone;   Drug: Sirolimus;   Other: Observation Only
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Intervention:   Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)
    Sponsors:   University of Pennsylvania;   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplasia;   Lymphoma
    Interventions:   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide;   Drug: Mycophenolate Mofetil;   Drug: Cyclophosphamide
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
    Not yet recruiting

  • Condition:   Rhabdomyosarcoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling;   Drug: Irinotecan;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Drug: Doxorubicin;   Drug: Dexrazoxane;   Drug: ^1^1C-methionine
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia With BCR-ABL1;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Drug: Ponatinib;   Biological: Rituximab;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Uveal Neoplasms;   Melanoma, Uveal
    Intervention:   Biological: Tumor Infiltrating Lymphocytes (TIL)
    Sponsor:   Udai Kammula
    Recruiting

  • Conditions:   Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA);   Severe Aplastic Anemia (SAA)
    Intervention:   Biological: Umbilical Cord Blood
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Biliary Tract Cancer;   Cholangiocarcinoma;   Biliary Tract Neoplasms
    Intervention:   Biological: Tumor Infiltrating Lymphocytes (TIL)
    Sponsor:   Udai Kammula
    Recruiting

  • Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Polatuzumab Vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Vincristine Placebo;   Drug: Prednisone;   Drug: Polatuzumab vedotin Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CRLF2 Positive;   Recurrent Ph-Like Acute Lymphoblastic Leukemia;   Refractory Ph-Like Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Ruxolitinib Phosphate;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Acute Lymphoblastic Leukemia;   Mixed Lineage Leukemia;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   Juvenile Myelomonocytic Leukemia
    Intervention:   Device: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Biological: Ofatumumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Ponatinib;   Drug: Ponatinib Hydrochloride;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Relapsed/Refractory Chronic Lymphocytic Leukemia
    Interventions:   Biological: KTE-X19;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   AIDS-Related Lymphoma;   Ann Arbor Stage II Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma;   CD20 Negative;   CD20 Positive;   Human Immunodeficiency Virus Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Biological: KTE-X19;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   T Acute Lymphoblastic Leukemia;   T Lymphoblastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Nelarabine;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Venetoclax;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Refractory Diffuse Large B Cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-Cell Lymphoma;   Transformed Follicular Lymphoma (TFL);   Primary Mediastinal B-cell Lymphoma (PMBCL);   High Grade B-cell Lymphoma (HGBCL)
    Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Biological: KTE-C19;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Relapsed/Refractory Mantle Cell Lymphoma
    Interventions:   Biological: KTE-X19;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Refractory Cancer;   Recurrent Cancer;   Solid Tumor, Adult;   Cancer
    Interventions:   Biological: IMA203 Product;   Device: IMADetect
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Refractory Acute Myelogenous Leukemia;   Relapsed Acute Myelogenous Leukemia
    Intervention:   Biological: FATE-NK100
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Solid Tumor, Adult;   Cancer;   Hepatocellular Carcinoma;   Hepatocellular Cancer;   Nonsmall Cell Lung Cancer;   Liver Cancer;   Lung Cancer
    Interventions:   Drug: IMA202 Product;   Device: IMA_Detect
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Solid Tumor;   Cancer;   Head and Neck Squamous Cell Carcinoma;   Non-small Cell Lung Cancer
    Interventions:   Biological: IMA201 Product;   Diagnostic Test: IMA_Detect;   Diagnostic Test: ACT-HLA
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Systemic Scleroderma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Non-Small Cell Lung Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: ROR1 CAR-specific Autologous T-Lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Multiple Myeloma;   Immune System Diseases
    Intervention:   Drug: CAR138 T Cells
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Myelodysplasia
    Intervention:   Device: Alpha Beta T cell depletion
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Follicular Lymphoma;   Marginal Zone Lymphoma;   Indolent Non-Hodgkin Lymphoma
    Interventions:   Biological: axicabtagene ciloleucel;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   ALL, Childhood;   ALL
    Interventions:   Drug: Ruxolitinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Vincristine;   Drug: Pegaspargase;   Drug: Rituximab;   Drug: Methotrexate (Intrathecal Administration);   Drug: Methotrexate (Intravenous Administration);   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Thioguanine;   Drug: Methotrexate Oral Product
    Sponsors:   University of Chicago;   Incyte Corporation
    Not yet recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Thymoglobulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Procedure: Bone marrow infusion;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Biological: Donor mesenchymal stem cell infusions;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Biological: FATE-NK100;   Drug: Interleukin-2
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Solid Tumor
    Interventions:   Drug: KITE-718;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Device: MAGE - A3/A6 Screening Test
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   Lymphoma;   Myeloma;   Leukemia
    Intervention:   Biological: Kappa CD28 T cells
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Biological: pembrolizumab;   Drug: doxorubicin;   Drug: vinblastine;   Drug: dacarbazine;   Drug: cyclophosphamide;   Drug: vincristine;   Drug: prednisone/prednisolone;   Drug: bleomycin;   Drug: etoposide;   Radiation: Radiotherapy (RT)
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Metastatic Cancer;   Recurrent Cancer;   Solid Tumor;   Renal Cell Carcinoma;   Urothelial Carcinoma;   NSCLC;   Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck
    Interventions:   Drug: IRX 2;   Drug: Nivolumab
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  • Conditions:   Advanced Solid Tumors;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
    Interventions:   Drug: FT500;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Atezolizumab;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Fate Therapeutics
    Recruiting

  • Conditions:   Lymphomatoid Granulomatosis;   Granulomatosis, Lymphomatoid;   Non-Hodgkins Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Biological: Interferon;   Drug: Rituxan and EPOCH
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   National Cancer Institute (NCI);   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Triple Negative Breast Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Drug: Dose-dense Doxorubicin or dose-dense Epirubicin;   Drug: Cyclophosphamide
    Sponsors:   Hoffmann-La Roche;   Breast International Group;   Alliance Foundation Trials (AFT);   Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU);   Frontier Science and Technology Research Foundation Inc (FS)
    Recruiting

  • Condition:   Juvenile Myelomonocytic Leukemia
    Interventions:   Biological: Stem Cell Transplant;   Drug: Preparative Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
    Interventions:   Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Neuroblastoma;   Medulloblastoma
    Interventions:   Drug: Nifurtimox;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   Giselle Sholler;   Bayer
    Recruiting

  • Condition:   Peripheral T Cell Lymphoma
    Intervention:   Drug: Nivolumab and EPOCH
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Condition:   Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Previously Untreated Peripheral T-cell Lymphoma
    Interventions:   Drug: CC-486 Administration;   Drug: CHOP Administration
    Sponsors:   Weill Medical College of Cornell University;   Celgene Corporation
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PEG-Asparaginase;   Drug: Methotrexate;   Drug: 6-MP (6-Mercaptopurine);   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Leucovorin;   Drug: Dexamethasone;   Other: Blood draw;   Device: CT/PET scans
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Shire;   Duke University;   Weill Medical College of Cornell University;   Lehigh Valley Health Network
    Recruiting

  • Conditions:   Medulloblastoma;   Central Nervous System Embryonal Tumors
    Interventions:   Drug: Induction;   Drug: Single Cycle Intensive Chemotherapy;   Drug: Tandem 3 Cycle Intensive Chemotherapy
    Sponsors:   Nationwide Children's Hospital;   Children's Hospital Los Angeles
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Neuroblastoma
    Intervention:   Biological: Hu3F8 With GM-CSF
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Y-mAbs Therapeutics
    Recruiting

  • Condition:   Inflammatory Breast Cancer (IBC)
    Interventions:   Drug: Ruxolitinib;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   Dana-Farber Cancer Institute;   Incyte Corporation
    Recruiting

  • Condition:   Crohn's Disease
    Interventions:   Biological: autologous CD34-selected peripheral blood stem cells transplant;   Drug: Alemtuzumab;   Drug: ATG;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: G-CSF;   Drug: Mesna
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: Rituximab;   Drug: Etoposide;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Doxorubicin Hydrochloride
    Sponsors:   Weill Medical College of Cornell University;   Genentech, Inc.;   Massachusetts General Hospital;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Peripheral T-cell Lymphomas;   Lymphoproliferative Disorders;   Immune System Diseases
    Interventions:   Drug: IOC;   Drug: GVHD prophylaxis;   Drug: RIC;   Procedure: allo HCT
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Medulloblastoma;   Untreated Childhood Medulloblastoma
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Advanced Malignant Neoplasm;   Recurrent Malignant Neoplasm;   Refractory Malignant Neoplasm
    Interventions:   Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Eribulin Mesylate;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Biological: Nivolumab;   Drug: Olaparib;   Drug: Oxaliplatin;   Drug: Paclitaxel;   Biological: Pembrolizumab;   Drug: Pemetrexed Disodium;   Drug: Selinexor;   Drug: Topotecan Hydrochloride
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Interventions:   Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy;   Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
    Sponsors:   New York Medical College;   St. Baldrick's Foundation
    Recruiting

  • Conditions:   Lymphoproliferative Disorders;   Autoimmune Lymphoproliferative;   Primary T-cell Immunodeficiency Disorders;   Immune System Diseases;   Common Variable Immunodeficiency
    Interventions:   Drug: Immunosuppression Only Conditioning (IOC);   Drug: Reduced Intensity Conditioning (RIC);   Drug: GVHD Prophylaxis;   Procedure: Allogeneic HSC
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Condition:   Advanced Follicular Lymphoma
    Interventions:   Drug: Obinutuzumab;   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone/Prednisolone/Methylprednisolone;   Drug: Vincristine
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Condition:   Newly Diagnosed Ewing Sarcoma
    Interventions:   Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Drug: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*;   Drug: Temozolomide;   Drug: Irinotecan;   Drug: Mesna;   Drug: Dexrazoxane;   Drug: G-CSF
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Triple-negative Breast Cancer
    Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Placebo;   Drug: Nab-paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Filgrastim;   Drug: Pegfilgrastim
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Copanlisib (BAY80-6946);   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bendamustine;   Drug: Prednisone
    Sponsor:   Bayer
    Recruiting

  • Condition:   Relapsed or Refractory Systemic Light Chain Amyloidosis
    Interventions:   Drug: IXAZOMIB;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: cyclosporine;   Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant;   Drug: horse anti-thymocyte globulin (ATG);   Drug: rabbit anti-thymocyte globulin (ATG);   Drug: methotrexate;   Drug: fludarabine;   Drug: cyclophosphamide;   Radiation: low-dose total body irradiation (TBI);   Procedure: Immunosuppressive Therapy (IST)
    Sponsor:   Michael Pulsipher, MD
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 25 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM);   Drug: Tacrolimus;   Drug: Methotrexate;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC)
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Primary T-cell Immunodeficiency Disorders;   Common Variable Immunodeficiency;   Immune System Diseases;   Autoimmune Lymphoproliferative;   Lymphoproliferative Disorders
    Interventions:   Drug: Immunosuppression Only Conditioning;   Drug: Reduced Intensity Conditioning;   Drug: Myeloablative Conditioning;   Drug: GVHD Prophylaxis;   Procedure: Allo BMT
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Immunodeficiencies;   Immune Dysregulation Syndromes
    Intervention:   Device: Apha/beta T and CD19+ cell depletion using CliniMACS device
    Sponsors:   Children's Hospital of Philadelphia;   University of California, San Francisco
    Recruiting

  • Conditions:   Malignant Rhabdoid Tumor;   Atypical Teratoid Rhabdoid Tumor
    Interventions:   Drug: alisertib;   Drug: methotrexate;   Drug: cisplatin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: topotecan;   Drug: vincristine;   Procedure: Surgical resection;   Radiation: Radiation therapy
    Sponsors:   St. Jude Children's Research Hospital;   Millennium Pharmaceuticals, Inc.;   Takeda Pharmaceuticals U.S.A., Inc.
    Recruiting

  • Condition:   Precursor Cell Lymphoblastic Leukemia-Lymphoma
    Interventions:   Drug: Daratumumab;   Drug: Vincristine;   Drug: Prednisone;   Drug: Doxorubicin;   Biological: Peg-asparaginase;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: 6-mercaptopurine;   Drug: Methotrexate
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: ITMHA;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Bortezomib;   Drug: Vorinostat;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Leucovorin Calcium;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Vincristine
    Sponsors:   St. Jude Children's Research Hospital;   Gateway for Cancer Research;   Texas Children's Hospital
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis;   Biological: Haplo HCT ≥55 and < 65 years old;   Biological: Haplo HCT ≥65 and ≤75 years old
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Biological: Pembrolizumab (K);   Drug: Placebo (P);   Drug: Paclitaxel (X);   Drug: Doxorubicin hydrochloride (A);   Drug: Epirubicin (E);   Drug: Cyclophosphamide (C);   Drug: Endocrine therapy;   Radiation: Radiation therapy;   Procedure: Surgery
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia (ALL)
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: PEG-asparaginase;   Drug: Vincristine;   Drug: Intrathecal (IT) Methotrexate;   Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate);   Drug: 6-Mercaptopurine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin
    Sponsors:   Amgen;   Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator;   Innovative Therapies For Children with Cancer Consortium
    Recruiting

  • Condition:   Medulloblastoma
    Interventions:   Radiation: Craniospinal Irradiation with boost to the primary tumor site;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Vincristine;   Drug: Vismodegib;   Drug: Pemetrexed;   Drug: Gemcitabine;   Other: Aerobic Training;   Other: Neurocognitive Remediation
    Sponsors:   St. Jude Children's Research Hospital;   Genentech, Inc.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematological Malignancy;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Myelodysplastic Syndromes;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Biological: Cord blood stem cells;   Drug: Valproic Acid;   Drug: Fludarabine;   Drug: cytoxan;   Drug: Thiotepa;   Biological: TBI
    Sponsor:   Alla Keyzner
    Recruiting

  • Conditions:   Cellular Ependymoma;   Childhood Anaplastic Ependymoma;   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Clear Cell Ependymoma;   Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Papillary Ependymoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vincristine Sulfate Liposome
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Squamous Cell Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Metastatic Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharynx Squamous Cell Carcinoma;   Paranasal Sinus Squamous Cell Carcinoma;   Hypopharynx Squamous Cell Carcinoma;   Larynx Squamous Cell Carcinoma
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Drug: IRX-2 Regimen
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Not yet recruiting

  • Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab vedotin;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Tocilizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Lenalidomide;   Biological: Obinutuzumab;   Drug: Prednisone;   Drug: Umbralisib;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Enzastaurin Hydrochloride;   Other: R-CHOP + placebo
    Sponsor:   Denovo Biopharma LLC
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B-cell Non Hodgkin Lymphoma;   Pre B-Cell Acute Lymphoblastic Leukaemia
    Interventions:   Drug: Blinatumomab;   Drug: Dexamethasone
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Amgen
    Recruiting

  • Conditions:   Colorectal Cancer;   Platinum-resistant Ovarian Cancer;   Appendiceal Cancer
    Interventions:   Biological: ONCOS-102;   Drug: Durvalumab
    Sponsors:   Ludwig Institute for Cancer Research;   Cancer Research Institute, New York City;   MedImmune LLC;   Targovax ASA
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: POM;   Drug: Steroids;   Drug: PLD;   Drug: CFZ;   Drug: BTZ;   Drug: CLA;   Drug: Other drugs;   Drug: CY
    Sponsors:   Oncotherapeutics;   Celgene Corporation
    Recruiting

  • Conditions:   Diffuse Large Cell Lymphoma;   Burkitt's Lymphoma;   High Grade B-cell Lymphoma
    Interventions:   Drug: Rituximab;   Drug: IT Cytarabine
    Sponsor:   New York Medical College
    Recruiting

  • Condition:   Prostate Cancer
    Interventions:   Procedure: Bone marrow transplantation;   Drug: Cytoxan;   Drug: testosterone cypionate
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia, Pediatric
    Interventions:   Drug: Pegaspargase;   Drug: Erwinia asparaginase;   Drug: Cyclophosphamide;   Drug: CYTARABINE;   Drug: DASATINIB;   Drug: DEXAMETHASONE;   Drug: Dexrazoxane;   Drug: Doxorubicin;   Drug: ETOPOSIDE;   Drug: HYDROCORTISONE;   Drug: LEUCOVORIN CALCIUM;   Drug: MERCAPTOPURINE;   Drug: METHOTREXATE;   Drug: NELARABINE;   Drug: Vincristine
    Sponsors:   Dana-Farber Cancer Institute;   Servier
    Recruiting

  • Conditions:   Relapsed/Refractory Diffuse Large B Cell Lymphoma;   Relapsed/Refractory Primary Mediastinal B Cell Lymphoma;   Relapsed/Refractory Transformed Follicular Lymphoma;   Relapsed/Refractory High-Grade B-Cell Lymphoma
    Intervention:   Biological: Axicabtagene Ciloleucel
    Sponsor:   Kite, A Gilead Company
    Available

  • Condition:   B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab Vedotin;   Drug: Rituxumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Tocilizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Multiple Myeloma;   CLL;   Chronic Lymphocytic Leukemia;   Lymphoma
    Interventions:   Radiation: Total Body Irradiation;   Procedure: Haploidentical Stem Cell Transplantation;   Biological: CD56-Enriched Donor Lymphocyte Infusion;   Drug: Bendamustine;   Drug: Fludarabine;   Drug: Rituximab
    Sponsors:   Noah Merin;   Miltenyi Biotec GmbH;   Teva Pharmaceutical Industries
    Recruiting

  • Condition:   Multiple Myeloma
    Intervention:   Biological: JCARH125
    Sponsors:   Juno Therapeutics, Inc.;   Celgene Corporation
    Recruiting

  • Condition:   Sickle Cell Disease
    Intervention:   Drug: CD34 selected T-cell depleted allogeneic SCT
    Sponsors:   New York Medical College;   Children's Hospital & Research Center Oakland;   Medical College of Wisconsin;   Washington University School of Medicine;   Tufts Medical Center;   University of California, San Francisco;   University of California, Los Angeles;   Miltenyi Biotec GmbH;   Lurie Children's Hospital of Chicago
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting

  • Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Chemoimmunotherapy;   Drug: Obinutuzumab
    Sponsors:   Acerta Pharma BV;   AstraZeneca
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   High-Risk Neuroblastoma;   NMYC Gene Amplification
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Drug: Isotretinoin;   Drug: Melphalan;   Biological: Sargramostim;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Vincristine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   BCR/ABL1 Fusion Protein Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Medulloblastoma
    Interventions:   Drug: Bevacizumab;   Drug: Thalidomide;   Drug: Celecoxib;   Drug: Fenofibric acid;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Etoposide phosphate;   Drug: Cytarabine
    Sponsor:   Medical University of Vienna
    Recruiting

  • Condition:   Triple Negative Breast Cancer
    Interventions:   Drug: Placebo;   Drug: Atezolizumab
    Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Fludarabine;   Drug: Cytoxan;   Radiation: Total Body Irradiation;   Procedure: Allogeneic Blood or Marrow Transplant;   Procedure: Peripheral Blood Stem Cell Transplant;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: EG12014;   Drug: Herceptin
    Sponsor:   EirGenix, Inc.
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Incyte Corporation;   Children's Oncology Group
    Recruiting

  • Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated Recombinant L-Asparaginase Erwinia Chrysanthemi;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma;   Neuroblastoma
    Interventions:   Drug: chemotherapy;   Drug: venetoclax
    Sponsors:   AbbVie;   Roche-Genentech
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Standard of Care;   Genetic: JCAR017
    Sponsor:   Celgene
    Recruiting

  • Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors
    Interventions:   Drug: Standard Therapy;   Drug: AMG 386 with or without Trastuzumab;   Drug: AMG 479 (Ganitumab) plus Metformin;   Drug: MK-2206 with or without Trastuzumab;   Drug: AMG 386 and Trastuzumab;   Drug: T-DM1 and Pertuzumab;   Drug: Pertuzumab and Trastuzumab;   Drug: Ganetespib;   Drug: ABT-888;   Drug: Neratinib;   Drug: PLX3397;   Drug: Pembrolizumab - 4 cycle;   Drug: Talazoparib plus Irinotecan;   Drug: Patritumab and Trastuzumab;   Drug: Pembrolizumab - 8 cycle;   Drug: SGN-LIV1A;   Drug: Durvalumab plus Olaparib;   Drug: SD-101 + Pembrolizumab;   Drug: Tucatinib
    Sponsor:   QuantumLeap Healthcare Collaborative
    Recruiting

  • Condition:   Acute Leukemia (Category)
    Interventions:   Genetic: HSV-Tk;   Other: T-cell depleted or T-cell replete strategies
    Sponsor:   MolMed S.p.A.
    Recruiting

  • Condition:   Richter Syndrome
    Interventions:   Drug: Venetoclax;   Other: DA-EPOCH-R
    Sponsors:   Dana-Farber Cancer Institute;   Genentech, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Leukemia, Acute Myeloid;   Myeloid Leukemia, Acute;   Leukemia, Myeloid, Acute;   Acute Myelogenous Leukemia;   Leukemia, Acute Myelogenous;   Myelogenous Leukemia, Acute;   AML;   Bone Marrow Transplant
    Interventions:   Drug: Iomab-B;   Drug: Conventional Care;   Procedure: HCT
    Sponsor:   Actinium Pharmaceuticals
    Recruiting

  • Conditions:   Recurrent Adult Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   TNFRSF8 Positive
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Breast Cancer;   Adenocarcinoma of the Breast
    Interventions:   Radiation: PBI;   Other: PBI with chemotherapy
    Sponsor:   Richard Zellars
    Recruiting

  • Conditions:   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Stage I Diffuse Large B-Cell Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Carfilzomib;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Rituximab
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Amgen
    Recruiting

  • Conditions:   CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present;   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   TNFRSF8 Positive
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Sarcoma
    Interventions:   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Fosaprepitant Dimeglumine;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Mesna;   Drug: Ondansetron;   Other: Questionnaire Administration;   Drug: Rolapitant;   Drug: Rolapitant Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CCND1 Positive;   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Avelumab;   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Drug: Ibrutinib;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab;   Biological: Utomilumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphocyte-Rich Classical Hodgkin Lymphoma;   Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma;   Recurrent Mixed Cellularity Classical Hodgkin Lymphoma;   Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma;   Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma;   Refractory Mixed Cellularity Classical Hodgkin Lymphoma;   Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   Northwestern University;   Merck Sharp & Dohme Corp.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Lymphoma
    Interventions:   Dietary Supplement: Ascorbic Acid;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Drug: Gemcitabine Hydrochloride;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Placebo;   Other: Questionnaire Administration;   Biological: Rituximab
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting